2888704-84-3
2888704-84-3
Chemical Structure
Cirtociclib
Synonym(s): BLU-222
- CAS No.: 2888704-84-3
- Formula:C15H17F2N7O2
- Molecular Weight:365.34
InChIKey: IFJSYTKOMJJYNP-UHFFFAOYSA-N
SMILES: FC(OC1=CC(NC2=NC3=C(C=NN3CC4CCOCC4)N=C2)=NN1)F
Biological Activity: Cirtociclib (BLU-222) is an orally active and highly selective CDK2 inhibitor. Cirtociclib disrupts Rb signaling and causes G1 arrest and apoptosis in CCNE1-amplified endometrial cancer cells[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cirtociclib | 99.31% | Cirtociclib (BLU-222) is an orally active and highly selective CDK2 inhibitor. Cirtociclib disrupts Rb signaling and causes G1 arrest and apoptosis in CCNE1-amplified endometrial cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Talbot T, et al. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal. Cancer Gene Ther. 2023 Jul;30(7):955-963. [Content Brief]
- [2]. House N, et al. BLU-222, a potent and highly selective CDK2 inhibitor, demonstrated antitumor activity as monotherapy and as combination treatment in CCNE1-aberrant endometrial cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 1959-1959.
- [3]. Luo L, et al. Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer[J]. Cancer Research, 2024, 84(9_Supplement): PO1-18-05-PO1-18-05.
